Company news
SciSparc Ltd. news in 2024
SciSparc Ltd.'s news releases, calls and decks from 2024, newest first.
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
December 30, 2024
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
December 15, 2024
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 29, 2024
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 25, 2024
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 22, 2024
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 17, 2024
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 15, 2024
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 10, 2024
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 22, 2024
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 21, 2024
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 18, 2024
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 15, 2024
SciSparc Updates Regarding the Status of the AutoMax Merger
August 13, 2024
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 16, 2024
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 15, 2024
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 15, 2024
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 7, 2024
SciSparc Secures Strategic Advantage with Grant of European Patent
May 30, 2024
SciSparc to Acquire AutoMax
April 10, 2024
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 26, 2024
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 17, 2024
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 13, 2024
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 7, 2024
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 6, 2024
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 5, 2024
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 28, 2024
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 26, 2024
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 28, 2024
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 23, 2024
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 18, 2024